Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
NKTR Nektar Therapeutics
2.880
+0.080+2.86%
Post Mkt Price
2.8800.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-5.20% 23.63M -23.81% 21.59M 4.97% 24.82M -33.36% 101.91M
Operating revenue
-5.20% 23.63M -23.81% 21.59M 4.97% 24.82M -33.36% 101.91M
Cost of revenue
-6.38% 4.97M -33.29% 5.12M -7.66% 5.32M 27.83% 24.9M
Gross profit
-4.88% 18.65M -20.29% 16.47M 9.03% 19.51M -42.29% 77.01M
Operating expense
-57.87% 56.12M -51.66% 63.26M 5.74% 134.59M 1.90% 523.11M
Selling and administrative expenses
-23.53% 22.53M -30.57% 20.52M -13.70% 27.34M 17.35% 122.84M
-General and administrative expense
-23.53% 22.53M -30.57% 20.52M -13.70% 27.34M 17.35% 122.84M
Research and development costs
-67.62% 33.59M -57.81% 42.74M 12.18% 107.25M -2.06% 400.27M
Operating profit
67.01% -37.47M 57.54% -46.79M -5.20% -115.09M -17.42% -446.1M
Net non-operating interest income expense
61.30% -4.9M 49.92% -6.13M 39.97% -7.13M -137.55% -44.74M
Non-operating interest income
1,464.89% 2.05M 29.70% 1.1M -72.03% 395K -85.95% 2.57M
Non-operating interest expense
-45.68% 6.95M -44.78% 7.23M -43.37% 7.53M 27.47% 47.31M
Other net income (expense)
-405.71% -16.83M -3,808.77% -106.05M 2,098.25% 31.95M 28.23% -32.43M
Gain on sale of security
-- -- -- -- 2,190.49% 33.43M -- -8.02M
Special income (charges)
-- -16.83M -- -106.05M -- -1.48M -- 0
-Less:Restructuring and merger&acquisition
-- 10.61M -- 106.05M -- 1.48M -- --
-Less:Impairment of capital assets
-- 1.2M -- -- -- -- -- --
-Less:Other special charges
-- 5.02M -- -- -- -- -- --
-Write off
-- -- -- -- -- -- -- 0
Other non- operating income (expenses)
-- -- -- -- -- -- -- -24.41M
Income before tax
54.32% -59.2M -27.01% -158.97M 26.54% -90.27M -17.87% -523.28M
Income tax
-238.39% -155K -71.99% 100K 36.96% 126K 12.98% 557K
Net income
54.47% -59.05M -26.73% -159.07M 26.49% -90.39M -17.86% -523.84M
Net income continuous Operations
54.47% -59.05M -26.73% -159.07M 26.49% -90.39M -17.86% -523.84M
Minority interest income
Net income attributable to the parent company
54.47% -59.05M -26.73% -159.07M 26.49% -90.39M -17.86% -523.84M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
54.47% -59.05M -26.73% -159.07M 26.49% -90.39M -17.86% -523.84M
Basic earnings per share
55.71% -0.31 -23.19% -0.85 27.94% -0.49 -14.86% -2.86
Diluted earnings per share
55.71% -0.31 -23.19% -0.85 27.94% -0.49 -14.86% -2.86
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
CEO: Mr. Howard W. Robin
Market: NASDAQ
Listing Date: 05/06/1994
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist